Aclaris ham­mered as hair loss drug flops in PhII, days af­ter FDA took is­sue with Es­ka­ta ads

The top­i­cal treat­ment for alope­cia area­ta that Aclaris Ther­a­peu­tics li­censed from Rigel Phar­ma has failed a mid-stage study for alope­cia area­ta, leav­ing the com­pa­ny with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER